Novo Nordisk A/S
NOVO-B
Ранг среди акций
#105
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Цена акции
$39.75
Рыночная капитализация
$175.44B
Изменение (1 день)
1.32%
Изменение (1 год)
-25.55%
Страна
DK
Торговля Novo Nordisk A/S (NOVO-B)
Категория
Healthcare
Коэффициент P/B для Novo Nordisk A/S (NOVO-B)
Коэффициент P/B на February 2026 TTM: 7.11
Согласно последним финансовым отчетам и цене акций Novo Nordisk A/S, текущий коэффициент P/B (TTM) составляет 7.11. В конце 2024 он составлял 19.38.
История P/B для Novo Nordisk A/S с 2001 по 2026
Коэффициент P/B в конце каждого года
| Год | P/B | Изменить |
|---|---|---|
| 2026 (TTM) | 7.11 | -4.53% |
| 2025 | 7.45 | -61.56% |
| 2024 | 19.38 | -34.02% |
| 2023 | 29.37 | 15.39% |
| 2022 | 25.45 | 6.65% |
| 2021 | 23.87 | 51.77% |
| 2020 | 15.72 | -1.35% |
| 2019 | 15.94 | 12.22% |
| 2018 | 14.20 | -14.34% |
| 2017 | 16.58 | 16.48% |
| 2016 | 14.23 | -34.97% |
| 2015 | 21.89 | 29.23% |
| 2014 | 16.94 | 35.36% |
| 2013 | 12.51 | -0.67% |
| 2012 | 12.60 | 26.42% |
| 2011 | 9.97 | 0.88% |
| 2010 | 9.88 | 77.44% |
| 2009 | 5.57 | 9.91% |
| 2008 | 5.07 | -20.41% |
| 2007 | 6.36 | 25.26% |
| 2006 | 5.08 | 20.40% |
| 2005 | 4.22 | 11.39% |
| 2004 | 3.79 | 16.59% |
| 2003 | 3.25 | 4.96% |
| 2002 | 3.10 | -47.14% |
| 2001 | 5.86 | 0.00% |
Коэффициент P/B для аналогичных компаний или конкурентов
| Компания | P/B | Разница P/B | Страна |
|---|---|---|---|
| 34.4295 | 384.06% |
US
|
|
| 7.8748 | 10.72% |
US
|
|
| -84.9599 | -1,294.50% |
US
|
|
| 9.0001 | 26.54% |
US
|
|
| 8.4776 | 19.19% |
CH
|
